Sanofi ODYSSEY Phase 3 Clinical Trial Overview for Praluent

Sanofi ODYSSEY Phase 3 Clinical Trial Overview for Praluent The passage is a standard pharmaceutical promotional document describing clinical trial results and safety information for Praluent. It contains no allegations, financial flows, or connections to high‑profile political or intelligence actors, offering no actionable investigative leads. Key insights: ODYSSEY Phase 3 includes 14 global trials with >23,500 patients.; Primary endpoint met: LDL cholesterol reduction at week 24.; ODYSSEY OUTCOMES trial enrolling ~18,000 patients.